{"filing":{"accession_number":"0000950103-26-009416","cik":"0001771910","ticker":"ADCT","company_name":"ADC Therapeutics SA","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"dp248849_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_8k.htm"},"events":[{"id":13407,"run_id":11906,"accession_number":"0000950103-26-009416","anchor_item_number":"8.01","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"ADC Therapeutics announced a planned 17% global workforce reduction driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies. The company expects approximately $10 million in annualized cost savings and will incur one-time pre-tax charges of approximately $3 million for severance and termination costs, primarily in Q2 2026.","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10543,"accession_number":"0000950103-26-009416","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The press release discloses a planned 17% global workforce reduction with approximately $3 million in one-time severance and termination costs, expected to generate $10 million in annualized cost savings. This is a material operational restructuring decision that would affect a reasonable investor's assessment of the company's cost structure and financial flexibility, particularly given the company's cash runway concerns and regulatory milestones ahead.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T13:01:57.314772+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10544,"accession_number":"0000950103-26-009416","item_number":"8.01","item_title":"Other Events.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"ADC Therapeutics announced a planned 17% global workforce reduction driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies. The company expects approximately $10 million in annualized cost savings and will incur one-time pre-tax charges of approximately $3 million for severance and termination costs, primarily in Q2 2026. This is a material operational restructuring with quantified financial impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T13:01:57.314772+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10543,"accession_number":"0000950103-26-009416","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The press release discloses a planned 17% global workforce reduction with approximately $3 million in one-time severance and termination costs, expected to generate $10 million in annualized cost savings. This is a material operational restructuring decision that would affect a reasonable investor's assessment of the company's cost structure and financial flexibility, particularly given the company's cash runway concerns and regulatory milestones ahead.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T13:01:57.314772+00:00","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-24"},{"id":10544,"accession_number":"0000950103-26-009416","item_number":"8.01","item_title":"Other Events.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"ADC Therapeutics announced a planned 17% global workforce reduction driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies. The company expects approximately $10 million in annualized cost savings and will incur one-time pre-tax charges of approximately $3 million for severance and termination costs, primarily in Q2 2026. This is a material operational restructuring with quantified financial impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T13:01:57.314772+00:00","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-24"}]}